NCT04055168View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

February 10, 2020

Study Completion Date

February 10, 2020

Conditions
Dyslipidemia
Interventions
DRUG

AZD6615

AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.

DRUG

Placebo

Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.

Trial Locations (2)

21225

Research Site, Baltimore

91206

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT04055168 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects | Biotech Hunter | Biotech Hunter